Rakuten Securities Inc. Purchases New Position in Eli Lilly and Company (NYSE:LLY)

Rakuten Securities Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,414 shares of the company’s stock, valued at approximately $824,000. Eli Lilly and Company comprises about 0.7% of Rakuten Securities Inc.’s portfolio, making the stock its 29th largest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JGP Wealth Management LLC raised its position in Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after purchasing an additional 16 shares during the period. Cassia Capital Partners LLC grew its stake in Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after purchasing an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC increased its holdings in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after acquiring an additional 17 shares during the period. Patton Albertson Miller Group LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after acquiring an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. boosted its position in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $4.03 during trading on Wednesday, hitting $746.74. 2,569,799 shares of the company’s stock were exchanged, compared to its average volume of 2,215,511. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business has a 50-day simple moving average of $763.51 and a 200-day simple moving average of $657.01. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The stock has a market capitalization of $709.52 billion, a price-to-earnings ratio of 128.75, a PEG ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the company posted $2.09 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.